WST at a glance
West Pharmaceutical Services (WST, SEC CIK 105770) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on July 23, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), West Pharmaceutical Services (WST) reported revenue of $3.1 billion (up 6.3% from FY2024) and net income of $493.7 million. Diluted EPS was $6.79.
- As of June 30, 2026, 38 institutional investment managers tracked by SignalX reported holding West Pharmaceutical Services (WST) shares worth $11.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Favorite Annette F on September 15, 2026 of 2,524 shares at $365.00 per share.
- In the last 90 days, WST insiders reported 0 open-market purchases ($0) and 6 open-market sales ($5.4M) on Form 4, a net sale of $5.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.1B
- +6.3% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$5.4M
- 13F holders
- 38 funds
- $11.7B · −2 vs prior quarter
- Latest 8-K
- Jul 23, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Manufacturer of integrated containment and delivery systems for injectable drugs, including proprietary packaging and contract manufacturing
- Emphasis on patient-centric self-injection devices combined with connected health technologies for improved treatment adherence
- Strategic focus on integrated solutions combining packaging, delivery devices, and analytical lab services to enhance market leadership
- International sales accounted for 56.7% of net sales in 2025, highlighting significant global market presence
- Supply chain management involves single-source suppliers for critical raw materials, with increased inventory to mitigate supply interruption risks
Risk Factors
- Regulatory risk: U.S. tariffs and retaliatory tariffs in operational jurisdictions; impact on supply chain currently not material but dynamic and monitored closely
- Macroeconomic risk: $572.2 million cash held outside the U.S., exposing liquidity to foreign exchange volatility and global economic conditions
- Operational risk: $75 million purchase commitments in 2026 for raw materials and finished goods critical to manufacturing continuity
- Competitive risk: Sale of SmartDose® 3.5mL On-Body Delivery System to AbbVie, indicating potential competitive displacement in drug delivery system market
- Financial risk: Increased restructuring charges in 2025 of $23.3 million due to severance, depreciation, lease costs, and legal structure optimization impacting operating costs
AI summary of the WST 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly triggered cybersecurity risk: May 2026 attack exfiltrated data and encrypted systems
- Operational disruption: Global systems taken offline, temporarily interrupting operations before full recovery
- Regulatory exposure: Privacy noncompliance could cause financial losses and reputational damage
- Cybersecurity costs: Insurance limits may not cover damages or fines exceeding policy limits
AI summary of the WST 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Investor presentation attached as Exhibit 99.2 and available on West Pharmaceutical Services’ website
- Exhibit 99.2 contains the call materials investors need for fiscal-year 2026 results context
Item 1.01: Entry into a Material Definitive Agreement
- 10-year renewal strengthens West’s strategic partnership with Daikyo, in which West holds a 49% ownership interest
- Exclusive West licensing rights outside Japan support international product access and competitive positioning
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Michel Lagarde becomes President and CEO August 31, 2026, replacing retiring Eric Green
- Leadership continuity: Green exits the Board; Lead Independent Director Robert Friel becomes Chair
AI summaries of WST 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for WST
Don't miss the next WST filing
- Alerts as it files. A push when WST files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut WST, by share count.
- Ask anything. An AI agent that reads every WST filing and answers with sources.
WST alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HAUGEN JANET BRUTSCHEA | A | Sep 30, 2026 | 44 | $370.76 |
| Favorite Annette F | M | Sep 15, 2026 | 2,524 | - |
| Favorite Annette F | M | Sep 15, 2026 | 2,524 | $89.64 |
| Favorite Annette F | Sell | Sep 15, 2026 | 2,524 | $365.00 |
| Favorite Annette F | M | Sep 14, 2026 | 2,500 | - |
| Favorite Annette F | Sell | Sep 14, 2026 | 2,500 | $355.00 |
| Favorite Annette F | M | Sep 14, 2026 | 2,500 | $89.64 |
| Favorite Annette F | M | Sep 11, 2026 | 2,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.9B | $3.1B |
| Gross Profit | - | $998.5M | $1.1B |
| Operating Income | - | $569.9M | $584.9M |
| Net Income | - | $492.7M | $493.7M |
| Gross Margin | - | 34.5% | 35.9% |
| Op. Margin | - | 19.7% | 19.0% |
| Net Margin | - | 17.0% | 16.1% |
| Balance Sheet | |||
| Total Assets | $3.8B | $3.6B | $4.3B |
| Equity | $2.9B | $2.7B | $3.2B |
| ROE | - | 18.4% | 15.5% |
| Per Share | |||
| EPS | - | $6.69 | $6.79 |
| Cash Flow | |||
| Operating CF | - | $653.4M | $754.8M |
| CapEx | - | $377.0M | $285.9M |
Source: XBRL data in West Pharmaceutical Services (WST)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate WST share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 38 | $11.75B |
| Q1 2026 | 40 | $7.93B |
| Q4 2025 | 37 | $8.25B |
| Q3 2025 | 34 | $8.19B |
| Q2 2025 | 35 | $6.89B |
| Q1 2025 | 33 | $5.78B |
| Q4 2024 | 30 | $7.40B |
| Q3 2024 | 24 | $3.38B |
- FMR LLC (Fidelity)+2.33M (+186%)
- Morgan Stanley+124.3K (+9%)
- JPMorgan Chase & Co+121.1K (+12%)
- Goldman Sachs Group+87.2K (+12%)
- Dimensional Fund Advisors+60.2K (+13%)
- BNY Mellon−422.0K (-17%)
- AQR Capital Management−209.3K (-78%)
- Two Sigma Investments−207.4K (-92%)
- BlackRock−184.9K (-3%)
- Renaissance Technologies LLC−178.8K (-85%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 271 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
WST filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| 10-Q | Jul 23, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 8-K | May 20, 2026 | - | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| SC 13G | Apr 30, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
WST SEC filings: frequently asked questions
Are WST insiders buying or selling?
In the last 90 days, West Pharmaceutical Services (WST) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $5.4 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold WST stock?
As of June 30, 2026, the largest West Pharmaceutical Services (WST) holders among the 13F filers tracked by SignalX were BlackRock ($2.4 billion), Vanguard Capital Management LLC ($1.7 billion), Vanguard Portfolio Management LLC ($1.4 billion), FMR LLC (Fidelity) ($1.3 billion), State Street Corp ($1.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was WST's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), West Pharmaceutical Services (WST) reported revenue of $3.1 billion (up 6.3% from FY2024) and net income of $493.7 million. Diluted EPS was $6.79. The figures come from the XBRL data in the 10-K.
What are the main risks in WST's latest 10-K?
In the 10-K filed February 17, 2026, West Pharmaceutical Services (WST) flagged: Regulatory risk: U.S. tariffs and retaliatory tariffs in operational jurisdictions; impact on supply chain currently not material but dynamic and monitored closely. Macroeconomic risk: $572.2 million cash held outside the U.S., exposing liquidity to foreign exchange volatility and global economic conditions. (AI summary of the Risk Factors section.)
What did WST report in its latest 8-K?
West Pharmaceutical Services (WST) filed an 8-K on July 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Investor presentation attached as Exhibit 99.2 and available on West Pharmaceutical Services’ website.
What are the latest WST SEC filings?
West Pharmaceutical Services (WST) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on July 23, 2026 and a Form 4 insider filing on October 2, 2026.
What is WST's SEC CIK number?
West Pharmaceutical Services (WST)'s SEC Central Index Key (CIK) is 105770. EDGAR lists every WST filing under that number.
Ask anything about WST
The research agent reads WST's filings, financials, insider trades and 13F holders, then answers with sources.